The diverse efficacy of different PPARγ agonists in NAFLD and NASH reinforces that notion that the activation of the same PPAR subtype by different agonists does not necessarily lead to similar outcomes. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.